Patent Term Extension vs Adjustment: What’s the Difference and Why It Matters

If you build value around a patent, every day of exclusivity matters. Two tools can add days to a U.S. patent: Patent Term Adjustment and Patent Term Extension. They serve different problems and follow different rules.

Get them right, and you protect your runway. Mix them up, and you can leave time on the table or miss a hard deadline. This guide explains the differences in plain English and shows how to apply each step by step.

TL;DR

• Patent Term Adjustment (PTA) adds time for USPTO examination delays.
• Patent Term Extension (PTE) adds time for FDA or similar regulatory review.
• PTA is automatic at grant but must be checked and, if needed, challenged quickly.
• PTE is a separate application with a strict 60‑day post‑approval deadline.
• PTA generally applies to utility and plant patents issuing from applications filed on or after May 29, 2000 (design patents are not eligible).
• Courts have held that PTE may extend even a terminally disclaimed patent.
• After In re Cellect, PTA can expose claims to obviousness-type double patenting invalidity when PTA causes a patent to expire later than a proper ODP reference and no timely terminal disclaimer resolves the issue.
• When both apply, the order is base term, add PTA, then add PTE, subject to statutory caps.

The Basics of PTA and PTE

PTA and PTE both add time, but they start from different causes.

• Patent Term Adjustment fixes delays inside the Patent Office. Congress created guarantees for timely first actions and overall pendency. If the USPTO misses them, the patent term is adjusted day‑for‑day, minus periods attributable to applicant delay, which includes late replies beyond three months and other defined events.
• Patent Term Extension restores time lost to mandatory pre‑market review. If a product needed FDA or similar approval before sale, one patent that claims that product, its approved use, or its method of manufacture can be extended to reflect part of the testing phase and all of the approval phase.

Our patent lawyers help applicants distinguish between PTA and PTE early, understand calendar statutory deadlines, and take corrective action before lost patent term becomes irreversible.

The Statutes That Control

This foundational knowledge prevents costly filing errors by clarifying whether a delay stems from administrative backlogs or rigorous federal safety reviews.

• PTA lives in 35 U.S.C. 154(b), with implementing rules in 37 C.F.R. 1.702 to 1.705 and detailed procedures in the MPEP. It divides the USPTO delay into three buckets that practitioners call A, B, and C delays.
• PTE lives in 35 U.S.C. 156 and applies to drug products, human biologics, certain medical devices, and food or color additives that went through defined regulatory review periods.

Quick Reference Guide on PTA vs PTE

This side-by-side analysis allows practitioners to quickly distinguish between automatic administrative adjustments and the complex application process required for regulatory extensions.

How Patent Term Adjustment Works

Patent Term Adjustment (PTA) compensates for certain delays attributable to the USPTO. It covers three distinct categories of delay:

Type A Delay: Missed USPTO Deadlines

A delay accrues when the USPTO fails to meet specific statutory deadlines, including:

• Failure to issue a first Office action within 14 months of filing.
• Failure to act within four months after an applicant’s reply or other required submission.
• Failure to issue the patent within four months after payment of the issue fee and satisfaction of all outstanding requirements.

These are deadline-driven delays tied to discrete Office obligations.

Type B Delay: Excessive Overall Pendency

B delay applies when prosecution extends beyond three years from the application’s filing date to issuance. Certain periods are excluded from the three-year (B-delay) calculation, including:

• Time consumed by continued examination (RCE practice)
• §135 interferences or derivation proceedings
• Secrecy orders
• Appellate review

B delay focuses on total pendency rather than missed interim deadlines.

Type C Delay: Exceptional Proceedings

C delay accounts for time consumed by specific, less common proceedings, namely:

• Interferences or derivation proceedings
• Secrecy orders
• Successful appeals that result in allowance

Unlike A and B delays, the C delay is tied to particular procedural events rather than timing benchmarks.

Challenging, Calculating, and Limiting PTA

The USPTO posts a PTA number at grant. That number is not final unless you let it be. You can request reconsideration within two months of issue (extendable up to five additional months by petition and fee). If you still disagree after the Office decision, your exclusive judicial remedy is a civil action in the Eastern District of Virginia filed within 180 days of the USPTO’s reconsideration decision.

Two Federal Circuit guideposts shape PTA practice. Wyeth v. Kappos rejected the Office’s former “greater of A or B” approach and required proper addition of non-overlapping A and B delays. Supernus v. Iancu held that applicant delay cannot exceed the period when the applicant could have acted with reasonable efforts, prompting rule changes that narrowed several automatic deductions.

PTA also intersects with obviousness-type double patenting (ODP). The Federal Circuit’s In re Cellect decision held that ODP is assessed against a patent’s expiration as adjusted by PTA. This means that PTA can expose claims to invalidity unless resolved by a terminal disclaimer. 

Later decisions clarified limits on what can serve as an ODP reference, but the core point remains: PTA is vulnerable to ODP in a way PTE is not. If the PTA number on your issued patent looks wrong, Goldstein Patent Law can recompute the A/B/C delay, prepare the reconsideration request, and litigate PTA disputes when necessary.

How Patent Term Extension Works

PTE applies only when a product has to clear a regulatory review period before sale. It can extend a patent that claims:

• The approved product’s active ingredient (for drugs and biologics),
• A method of using the product for an approved use, or
• A method of manufacturing the product is used for the approved product.

Key limits are strict:

• Only one patent can be extended per approved product.
• The extension cannot exceed five years.
• The total effective life after first approval cannot exceed 14 years.
• The PTE application must be filed within 60 days of the product’s first approval.

The extension’s scope tracks the approval. During the extended period, rights are limited to the approved product and approved uses or the approved manufacturing method. Courts have confirmed that PTE can apply even if the patent is terminally disclaimed and that ODP does not, by itself, invalidate an otherwise proper PTE. Although PTE doesn’t cure claims that are independently invalid.

Practical Effects of Recent Cases

These legal updates provide the necessary insight to navigate how recent court rulings impact the final expiration dates of adjusted or extended patents.

• PTA stacking: Wyeth allows proper addition of distinct A and B delays. Always check Office math.
• Applicant delay: Supernus limits deductions to periods when you could have acted. Post‑2020 rules reflect that holding.
• ODP and PTA: In re Cellect applies ODP after adding PTA, so a terminal disclaimer can cut PTA short. In Allergan v. MSN (Fed. Cir. 2024), the court held that within a common-priority family, a later-filed, later-issued patent cannot serve as an ODP reference against the first-filed, first-issued patent, even if the first patent expires later due to PTA.
• ODP and PTE: Merck v. Hi‑Tech and Novartis v. Ezra confirm that PTE may extend a terminally disclaimed patent and that ODP does not undo a valid PTE.

Examples

Take a look at these cases to better anticipate how regulatory caps and double-patenting challenges might impact your specific intellectual property portfolio.

Pharma Product With Both PTA and PTE

A company files a new drug application and a core compound patent. USPTO delays generate 400 days of PTA. Years later, the FDA approves the drug. The patentee files a PTE request within 60 days of approval. The patent’s expiration date is first adjusted to reflect 400 days of PTA, and that PTA-adjusted expiration then serves as the baseline for calculating any PTE. 

The agencies calculate a regulatory review period that yields 1,460 days of extension, but the 14‑year post‑approval cap reduces it to 1,200 days. The patent’s final expiration is base term + 400 days PTA + 1,200 days PTE, and enforcement during the PTE period is limited to the approved product and uses.

Portfolio With PTA Facing ODP Risk

A device company prosecutes a family of related applications. The earliest patent receives 600 days of PTA. Later continuations issue with no PTA. A competitor challenges the PTA‑extended patent on ODP using later‑filed, earlier‑expiring family members. 

Under Cellect, ODP is assessed against the PTA‑adjusted expiry, but after Allergan, later‑filed, later‑issued patents are not proper ODP references against the first‑filed, first‑issued patent. The company still files protective terminal disclaimers in certain continuations to avoid future ODP risk that could cut PTA.

Actionable Steps / Checklist

Here’s a structured timeline and audit process you can follow to make sure that no days of earned extension are lost due to avoidable administrative errors.

• Be aware of the calendar hard deadlines: For PTE, 60 days from the product’s first approval date. Miss it, and PTE is usually lost. For PTA, 2 months from grant to request reconsideration (extendable), then 180 days from the USPTO decision to sue in E.D. Va. if needed.
• Audit the PTA number at grant: Recompute A/B/C delays. Next, confirm the Office did not subtract time you could not have avoided. After that, verify B‑delay exclusions, especially RCE time and appeal periods.
• Manage applicant delay proactively: Aim to respond within 3 months. Use the due care reinstatement only when justified. Avoid unnecessary deferrals, late issue fee payments, and supplemental filings that trigger deductions.
• Plan for ODP early: Map family claim scope to avoid patentably indistinct claims that expire on different dates. Use terminal disclaimers strategically where needed, noting they can truncate PTA but not PTE.
• Prepare a PTE file‑ready dossier: Track clinical and approval dates as they occur. Capture due diligence evidence. Identify the best single patent to extend, matching claims to the approved product or use.
• Document everything: Keep a clean chronology of regulatory milestones, Office actions, and responses to support PTA reconsideration or PTE calculations.

Glossary

Whenever you get confused with these technical words you see in your application, use this glossary as a reference guide on the concepts.

• Patent Term Adjustment (PTA): Added days to a patent for USPTO delays during examination, reduced by applicant delay.
• Patent Term Extension (PTE): Added time to one patent for a product that underwent regulatory review before marketing.
• A/B/C Delay: Short‑hand for the three PTA guarantees in 35 U.S.C. 154(b)(1)(A)–(C).
• RCE: Request for Continued Examination; time consumed is excluded from B‑delay.
• Regulatory Review Period: Statutory testing and approval phases used to compute PTE for drugs, biologics, devices, and certain additives.
• Obviousness‑Type Double Patenting (ODP): Judge‑made doctrine preventing unjustified patent term extension across patentably indistinct claims.
• Terminal Disclaimer: An applicant’s statement aligning a patent’s term with another patent; it’s a statutory hard stop for PTA, but doesn’t foreclose PTE.
• Eastern District of Virginia: Federal court with exclusive jurisdiction for PTA suits after USPTO reconsideration decisions.

FAQ

Q: Can A Patent Receive Both PTA And PTE?
A: A patent can get both PTA and PTE. PTA is applied first to the 20‑year term, and any PTE is added afterward, subject to the 5‑year and 14‑year caps.

Q: Does PTE Extend All Claims?
A: PTE won’t extend all claims. During the extended period, the enforceable scope is limited to the approved product and its approved uses or the approved manufacturing method.

Q: What If I Miss The 60‑Day PTE Deadline?
A: PTE is generally unavailable if you miss it. There are narrow statutory variants for specific circumstances, but you should treat 60 days as a hard stop.

Q: Where Do I Challenge A PTA Error?
A: If you want to challenge a PTA error, file a reconsideration request at the USPTO. If denied, file suit in the U.S. District Court for the Eastern District of Virginia within 180 days of the USPTO decision.

Q: Does An RCE Eliminate B‑Delay?
A: Time consumed by continued examination is excluded from B‑delay. Other A or C delays may still accrue.

Final Thoughts

PTA and PTE protect different slices of patent value. Treat PTA as a quality‑control step at grant and PTE as a race against a hard approval‑date clock. Build a calendar, verify the math, and align your claim strategy with the time you earn is time you can keep.

Whether you’re reviewing a newly issued patent for PTA errors or approaching FDA approval with PTE in mind, Goldstein Patent Law helps clients preserve every lawful day of patent exclusivity.